Informations générales (source: ClinicalTrials.gov)
A PHASE 1, OPEN-LABEL, DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND ANTITUMOR ACTIVITY OF PF-08052667 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS 18 YEARS OF AGE AND OLDER WITH BLADDER CANCER
Interventional
Phase 1
Pfizer (Voir sur ClinicalTrials)
novembre 2025
janvier 2033
23 juillet 2026
The purpose of this study is to learn how a new medicine called PF-08052667 works when
used by itself or together with another medicine called Bacillus Calmette Guerin (BCG),
and/or a medicine called sasanlimab.
This study is for adults who have a type of bladder cancer that hasn't spread into the
muscle layer of the bladder but is more likely to come back or grow. It includes people
whose cancer has come back or hasn't gone away after receiving standard treatments like
BCG. It may also include people who, based on their doctor's opinion, cannot receive
standard treatments or those treatments are not available to them.
The study has three parts:
- Part 1 (monotherapy dose escalation) will test PF-08052667 as a single-agent at
increasing dose levels in participants with certain bladder cancer whose disease has
worsened on or after standard treatments.
- Part 2 (combination dose escalation) will test PF-08052667 in combination with BCG
and/or sasanlimab (fixed dose) in participants with certain bladder cancer whose
disease has worsened on or after standard treatments.
- Part 3 (dose optimization and expansion) will further test PF-08052667 as a single
agent or in combination with BCG and/or sasanlimab, at the dose(s) based on findings
from Part 1 and Part 2 in participants with certain bladder cancer including those
who has never received standard treatments.
All participants will receive the study drug PF-08052667. Only participants in Part 2 and
Part 3 of the study will also receive BCG and/or sasanlimab. PF-08052667 will be given as
an intravesical infusion, which means it will be injected directly into the bladder.
Sasanlimab will be given as a subcutaneous injection, which means it will be injected
under the skin.
For all parts, treatment with study medicines will continue until either a participant
has decided to stop taking part in the study or is asked to leave the study for various
reasons or up to about 2 years, whichever occurs first. Duration of trial participation
for each participant will vary as long-term follow-up will continue after treatment
discontinuation until loss to-follow-up or death, or until the study is stopped by the
sponsor.
Etablissements
| Les établissements d'Île-de-France ayant mis à jour leurs données Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| CLCC INSTITUT GUSTAVE ROUSSY | Yohann LORIOT | 07/07/2026 08:00:07 | Contacter | ||
Critères
Tous
1. 18 years of age or older (or the minimum age of consent per local regulations)
2. Histological diagnosis of high-risk, non-muscle invasive urothelial carcinoma of the
bladder defined according to the WHO grading system as carcinoma in situ (CIS), with
or without concurrent T1/Ta papillary disease. Note: High-grade T1/Ta papillary
disease, in the absence of CIS, may be eligible for certain cohorts in Part 2 and 3
3. BCG unresponsive and BCG-exposed cohorts should have persistent or recurrent disease
after receiving at least 5 out of 6 doses of the BCG induction therapy.
4. Have refused or are ineligible or not appropriate for radical cystectomy
5. Tissue Requirement: Available tumor tissue within the last 6 months. On-treatment
tumor biopsy is optional, unless mandated based on emerging data, or participating
in the Biomarker Cohort, or for disease assessment
6. ECOG PS 0 or 1
EXCLUSION CRITERIA:
1. Concomitant anti-cancer therapy for Non-Muscle Invasive Bladder Cancer (NMIBC); and
prior radiation therapy to the bladder are not allowed
2. Renal or hepatic impairment; and hematologic abnormalities as defined in the
protocol
3. Participants with active, uncontrolled infection as specified in the protocol